Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.721 EUR 0.42% Market Closed
Market Cap: 490.5m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PHARM stock under the Base Case scenario is hidden EUR. Compared to the current market price of 0.721 EUR, Pharming Group NV is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PHARM Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.9
P/S
P/S
Price to Sales
1.9
vs History
82
vs Industry
77
Median 3Y
2.3
Median 5Y
2.8
Industry
6.5
Forward
1.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
3
Median 3Y
-39.7
Median 5Y
12.5
Industry
22
Forward
-22.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
6
Median 3Y
-43.5
Median 5Y
10.8
Industry
18.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
3
Median 3Y
-13.7
Median 5Y
6.9
Industry
23.4
More Details
2.5
P/B
P/B
Price to Book Value
2.5
vs History
88
vs Industry
34
Median 3Y
3.4
Median 5Y
3.8
Industry
2.2
More Details
1.7
EV/S
EV/S
Enterprise Value to Sales
1.7
vs History
82
vs Industry
69
Median 3Y
2
Median 5Y
2.4
Industry
7.1
Forward
1.5
More Details
1.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.9
vs History
82
vs Industry
70
Median 3Y
2.3
Median 5Y
2.7
Industry
8.7
More Details
39.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
39.4
vs History
17
vs Industry
2
Median 3Y
12.6
Median 5Y
10.9
Industry
3.3
Forward
-75.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
2
Median 3Y
-29.4
Median 5Y
7
Industry
3.1
Forward
-253.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
5
Median 3Y
-40.8
Median 5Y
10.2
Industry
4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
4
Median 3Y
-46.7
Median 5Y
13.1
Industry
2.6
More Details
3
EV/IC
EV/IC
Enterprise Value to IC
3
vs History
84
vs Industry
38
Median 3Y
3.6
Median 5Y
4.3
Industry
4.3
More Details

Multiples Across Competitors

PHARM Competitors Multiples
Pharming Group NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
Pharming Group NV
AEX:PHARM
490.5m EUR 1.9 -46.8 39.4 -136.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 091 518 -166 784.8 -202 529.9 -200 218.8
US
Abbvie Inc
NYSE:ABBV
303.1B USD 5.4 71.5 14.4 21.7
US
Amgen Inc
NASDAQ:AMGN
151.7B USD 4.5 37.1 15.3 27
US
Gilead Sciences Inc
NASDAQ:GILD
130.7B USD 4.5 272.3 10.7 13.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.6B USD 11.3 -232.7 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 007.6 -512.3 -557.8 -543
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27 16.7 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.2B USD 4.2 13.6 8.2 9.1
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.3 -63.9 -57.6
NL
argenx SE
XBRU:ARGX
31.7B EUR 16.4 43 317.4 -2 338.3
P/S Multiple
Revenue Growth P/S to Growth
NL
Pharming Group NV
AEX:PHARM
Average P/S: 3 190 327.1
1.9
14%
0.1
FR
Pharnext SCA
OTC:PNEXF
35 091 518
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.4
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.3
10%
1.1
US
E
Epizyme Inc
F:EPE
2 007.6
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
7%
0.6
US
S
Seagen Inc
F:SGT
19.3
30%
0.6
NL
argenx SE
XBRU:ARGX
16.4
37%
0.4
P/E Multiple
Earnings Growth PEG
NL
Pharming Group NV
AEX:PHARM
Average P/E: 77.4
Negative Multiple: -46.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 784.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
71.5
87%
0.8
US
Amgen Inc
NASDAQ:AMGN
37.1
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
272.3
187%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -232.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.3 N/A N/A
AU
CSL Ltd
ASX:CSL
27
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
12%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3 N/A N/A
NL
argenx SE
XBRU:ARGX
43
26%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
Pharming Group NV
AEX:PHARM
Average EV/EBITDA: 55.9
39.4
36%
1.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 529.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.4
14%
1
US
Amgen Inc
NASDAQ:AMGN
15.3
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.7
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.7
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.2
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.9 N/A N/A
NL
argenx SE
XBRU:ARGX
317.4
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
Pharming Group NV
AEX:PHARM
Average EV/EBIT: 19.8
Negative Multiple: -136.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 218.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.7
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
27
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.4
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -543 N/A N/A
AU
CSL Ltd
ASX:CSL
20.9
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.1
17%
0.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 338.3 N/A N/A

See Also

Summary
PHARM intrinsic value, competitors valuation, and company profile.
DCF Valuation
PHARM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PHARM stock valuation using valuation multiples.
Wall Street Estimates
PHARM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PHARM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 247,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.